nasdaq trvn industry biotechnology pharmaceutical headquarters king of prussia pennsylvania united states key people maxine gowen president and ceo michael lark cso website www.trevena.com trevena inc is a clinical stage biopharmaceutical company headquartered in king of prussia pennsylvania usa and is involved in the discovery and development of g protein coupled receptors gpcr biased ligands . trevena was founded with technology licensed from duke university which originated in the labs of company founders robert lefkowitz winner of the 2012 nobel prize in chemistry 1 and howard rockman . trevena s approach to drug discovery is based on utilizing ligand bias or functional selectivity at gpcr targets to produce drugs with improved efficacy and reduced side effect profiles . 2 in 2008 the company raised 25 million in a series a clarification needed financing round led by alta partners polaris ventures new enterprise associates healthcare ventures and yasuda economic development corporation . 3 trevena was named one of the top 15 us startups of 2008 by business week . 4 the company raised an additional 35 million usd in a b round of venture financing in the summer of 2010 . 5 trevena s lead program trv027 for acute heart failure targets the angiotensin receptor utilizing beta arrestin bias an approach that has shown numerous beneficial cardiovascular and renal actions in preclinical species . 6 7 trevena completed phase i clinical trials in 2010 . 8 phase 2 clinical trials on trv027 began in the spring of 2011 . 9 trevena is also developing trv130 a g protein biased ligand 10 for the intravenous treatment of acute moderate to severe post operative pain . the phase i first in human clinical trial of trv130 is complete . the drug was safe and generally well tolerated in this study with pharmacodynamic effects recapitulating its exciting preclinical profile . the next clinical study of trv130 will investigate analgesic efficacy and tolerability and will include intravenous morphine a gold standard post operative analgesic as a comparator . trevena s expertise lies in engineering biased ligands that activate only the beneficial signaling pathways downstream of a gpcr to unlock new biology and avoid drug adverse effects . 11 in addition to trv027 trevena s pipeline currently includes a clinical stage mu opioid biased ligand for post operative pain and discovery stage programs for chronic pain and parkinson s disease . 12 in early 2009 trevena entered into a collaborative agreement with ligand pharmaceuticals to identify biased ligands at numerous gpcrs from a large diverse chemical library . 13 later that year trevena received a competitively awarded american recovery and reinvestment act grand opportunities grant spanning two years and funding 7.65 million usd of research . 14 the company has disclosed specific interests in the mu opioid receptor and kappa opioid receptor . 15 in 2011 treveva received another nih grant as part of the nih blueprint neurotherapeutics network potentially worth up to 10m usd to support preclinical development of a delta opioid receptor biased ligand for major depressive disorder . 16 trevena has received funding from the michael j. fox foundation to explore the potential for delta opioid receptor biased ligands to treat parkinson s disease . 17 references edit the nobel prize in chemistry 2012 . nobelprize.org . 2012 10 10 . violin jonathan d. ; lefkowitz robert j. 2007 . arrestin biased ligands at seven transmembrane receptors . trends in pharmacological sciences . 28 8 416 22 . doi 10.1016 j.tips .2007.06.006 . pmid 17644195 . trevena inc announces 24 million series a financing . biospace.com . 2008 03 05 . most successful u.s. startups 2008 . . business week . 2008 12 31 . trevena lands 35m round to fund its first phii . fierce biotech . 2010 07 14 . violin jd ; dewire sm ; yamashita d ; rominger dh ; nguyen l ; schiller k ; whalen ej ; gowen m ; lark mw 2010 . selectively engaging arrestins at the angiotensin ii type 1 receptor reduces blood pressure and increases cardiac performance . the journal of pharmacology and experimental therapeutics . 335 3 572 9 . doi 10.1124 jpet .110.173005 . pmid 20801892 . boerrigter g ; lark mw ; whalen ej ; soergel dg ; violin jd ; burnett jr jc 2011 . cardiorenal actions of trv120027 a novel arrestin biased ligand at the angiotensin ii type i receptor in healthy and heart failure canines a novel therapeutic strategy for acute heart failure . circulation . heart failure . 4 6 770 8 . doi 10.1161 circheartfailure .111.962571 . pmid 21835984 . trevena initiates clinical development of trv120027 a first in class biased ligand . pipeline review . 2010 04 14 . trevena initiates phase 2 study of trv120027 for acute heart failure . pennsylvania biowatch . 2011 02 23 . dewire sm ; yamashita d ; et al. 2013 . a g protein biased ligand at the opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine . the journal of pharmacology and experimental therapeutics . 344 3 708 17 . doi 10.1124 jpet .112.201616 . pmid 23300227 . cs1 maint explicit use of et al. link exploring gpcrs as therapeutic targets . genetic engineering news . 2013 04 15 . trevena inc pipeline . trevena inc company website . 2010 01 01 . trevena to use ligand s library to identify gpcr therapeutics . genetic engineering news . 2009 02 06 . trevena awarded 7.65 million nih grant to accelerate identification and selection of biased gpcr ligands . business wire . 2009 11 03 . refining gpcr discovery approaches . genetic engineering news . 2011 04 15 . trevena receives major new award from nih to develop delta opioid biased ligand drug . business wire . 2011 08 18 . pathway validation of a biased delta opioid receptor ligand for pd symptoms & side effects relief . michael j. fox foundation . 2011 12 19 . external links edit official trevena site v t e pharmaceutical companies of the united states abbott laboratories acorda therapeutics actavis aderis pharmaceuticals adolor corporation alcon alexion pharmaceuticals alkermes allergan alza amgen amylin pharmaceuticals ariad pharmaceuticals aryx therapeutics avax technologies baxter international biocryst pharmaceuticals biogen biolex biovest biovista bradley pharmaceuticals bristol myers squibb cancervax century pharmaceuticals cephalon ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cotherix covance covidien cubist pharmaceuticals cutter laboratories cytosport cytrx danco laboratories dnaprint genomics epix pharmaceuticals eli lilly and company elorac endo pharmaceuticals ethicon endo surgery ethicon inc. forest laboratories galena biopharma genvec genentech genta gilead sciences hospira imclone systems institute for oneworld health intercept pharmaceuticals ista pharmaceuticals ivax corporation janssen biotech johnson & johnson kinetic concepts king pharmaceuticals kinray kv pharmaceutical leiner health products mallinckrodt martek biosciences corporation s. e. massengill company mckesson corporation mcneil laboratories melior discovery mentholatum merck & co. miles laboratories mylan myriad genetics naurex nereus pharmaceuticals northwest biotherapeutics norwich pharma services novabay pharmaceuticals nuvelo organon international ortho pharmaceutical ortho mcneil pharmaceutical osi pharmaceuticals ovation pharmaceuticals par pharmaceutical parke davis perrigo pfizer pharmaceutical product development prasco laboratories procter & gamble proteon therapeutics purdue pharma qualitest quark pharmaceuticals regeneron repros therapeutics rib x pharmaceuticals sarepta therapeutics savage laboratories schering plough g. d. searle & company sheffield pharmaceuticals smith kline & french spectrum pharmaceuticals sterling drug tanox tap pharmaceutical products tec laboratories teva pharmaceutical industries tiens biotech group titan pharmaceuticals trevena inc trubion upjohn upsher smith laboratories valeant pharmaceuticals ventria bioscience vertex pharmaceuticals verus pharmaceuticals vion pharmaceuticals inc. viropharma west pharmaceutical services wyeth zonite products corporation list of pharmaceutical companies companies portal retrieved from https en.wikipedia.org w index.php title trevena inc & oldid 743855542 categories companies listed on nasdaqpharmaceutical companies of the united statesbiotechnology companies of the united statescompanies based in montgomery county pennsylvaniaprivately held companies based in pennsylvaniahidden categories cs1 maint explicit use of et al.wikipedia articles needing clarification from may 2016companies with year of establishment missing navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 11 october 2016 at 17 15 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view